Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

Five separate mediation analyses found that adaptive coping had a significant association with each PWB subscale and self-efficacy. After controlling for self-efficacy, there remained separate ...

While autologous hematopoietic stem cell transplantation (aHSCT) has shown promise as a one-time treatment option for relapsing-remitting multiple sclerosis (RRMS), it’s still unclear what role aHSCT ...

Pavan Bhargava, MD, looks forward to the 2025 Annual Meeting of the American Academy of Neurology, where attendees will learn about the updated diagnostic criteria for relapsing-remitting multiple ...

I got married in 2014. I remember waking up with numb feet a couple months after we bought our house. But I didn’t think much of it at the time. I could always feel the floor again once I’d finished ...

A prospective study found evidence of serum neurofilament light (sNfL) level increases in patients affected by active forms of relapsing-remitting multiple sclerosis (RRMS); however, these findings ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...

A 49-year-old man with a long history of relapsing-remitting multiple sclerosis presents to the clinic for a routine follow-up visit. The patient was initially treated with glatiramer acetate ...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...

NEW YORK, Oct. 11, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...